Patents by Inventor James D. Marks

James D. Marks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10406225
    Abstract: Antibodies that bind to tumor associated antigen CD44 or to tumor associated antigen EphA2, are disclosed herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies, diagnostics, and screening methods.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: September 10, 2019
    Assignee: The Regents of the University of California
    Inventors: Yu Zhou, James D. Marks
  • Publication number: 20190256584
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used in methods to specifically bind and, in some embodiments, neutralize, botulinum neurotoxin and are therefore also useful in the treatment.
    Type: Application
    Filed: January 28, 2019
    Publication date: August 22, 2019
    Inventors: James D. Marks, Maria Consuelo Garcia Rodriguez, Jianbo Dong, Zhengda Sun
  • Patent number: 10379773
    Abstract: A storage unit for use within a dispersed storage network comprises an interface and a processing module operable to receive encoded data slices from a dispersed storage network client. The encoded data slices are associated with DSN logical addresses and the storage unit is allocated a range of DSN logical addresses in which the DSN logical addresses are found. The storage unit determines whether to store the encoded data slices in local memory of the storage unit or store them in remote memory. When the storage unit determines to store the encoded data slice to the remote memory it converts the DSN logical address into a local storage unit logical address and outputs the encoded data slices to the remote memory.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: August 13, 2019
    Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Andrew D. Baptist, Bart R. Cilfone, Greg R. Dhuse, Wesley B. Leggette, James L. Lester, Zachary J. Mark, Manish Motwani, Jason K. Resch
  • Patent number: 10372540
    Abstract: A method includes receiving, by a computing device of a dispersed storage network (DSN), a non-standard data access request regarding a set of encoded data slices, where the non-standard data access request includes a set of network identifiers of a set of storage units, a data identifier corresponding to data, and a data access function. The method further includes the computing device converting the non-standard data access request into one or more DSN slice names. The method further includes the computing device determining that the one or more DSN slice names are within a slice name range allocated to the computing device. When the one or more DSN slice names are within the slice name range, the method further includes the computing device executing the data access function regarding one or more encoded data slices corresponding to the one or more DSN slice names.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: August 6, 2019
    Assignee: International Business Machines Corporation
    Inventors: Andrew D. Baptist, Bart R. Cilfone, Greg R. Dhuse, Wesley B. Leggette, James L. Lester, Zachary J. Mark, Manish Motwani, Jason K. Resch
  • Publication number: 20190218298
    Abstract: Provided is an antibody that specifically binds human ?v?? and blocks binding of TGFp peptide to ?v?8, wherein the antibody binds to the specificity determining loop (SDL) of human ?8. In some embodiments, the antibody further binds to one, two, or all three of the human av-head domain, the al helix of human ?8, or the al helix of human ?8. In some embodiments, the antibody is humanized or chimeric. In some embodiments, the antibody is linked to a detectable label. Also provided is a method of enhancing an immune response in a human individual, comprising administering a sufficient amount of the antibody to the individual, thereby enhancing an immune response. Also provided are pharmaceutical compositions comprising the anti-?v?? antibodies or antigen-binding molecules thereof.
    Type: Application
    Filed: September 29, 2017
    Publication date: July 18, 2019
    Inventors: Stephen L. NISHIMURA, Jianlong LOU, James D. MARKS, Jody L. BARON, Yifan CHENG, Shenping WU, Anthony CORMIER, Naoki TAKASAKA
  • Patent number: 10308708
    Abstract: This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: June 4, 2019
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Isin N. Geren
  • Publication number: 20180208680
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: January 12, 2018
    Publication date: July 26, 2018
    Inventors: James D. Marks, Yongfeng Fan, Jianlong Lou, Maria Consuelo Garcia Rodriguez, Shude Yan, Isin Nergiz Geren, Wenwu Zhai, Subhendu Chakraborti
  • Publication number: 20180208679
    Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: January 12, 2018
    Publication date: July 26, 2018
    Inventors: James D. Marks, Isin N. Geren, Maria Consuelo Garcia, Jianlong Lou, Ali Razai
  • Publication number: 20180201681
    Abstract: The present disclosure relates to proteins that bind to CD83 and uses thereof, for example, in therapy, prophylaxis, diagnosis or prognosis.
    Type: Application
    Filed: November 9, 2017
    Publication date: July 19, 2018
    Applicants: DENDROCYTE BIOTECH PTY LTD, THE UNIVERSITY OF QUEENSLAND, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Therese Ann Seldon, David John Munster, Derek Nigel John Hart, Martina Louise Jones, Trent Phillip Munro, Stephen Michael Mahler, Yu Zhou, James D. Marks
  • Patent number: 9902780
    Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: February 27, 2018
    Assignee: The Regents of the University of Calfornia
    Inventors: James D. Marks, Maria Consuelo Garcia
  • Patent number: 9902781
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: February 27, 2018
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Maria Consuelo Garcia Rodriguez, Shude Yan
  • Patent number: 9845357
    Abstract: The present invention relates to ?v?8 antagonists, anti-?v?8 antibodies or immunoconjugates for reducing TGF? activation in an individual. Further provided are compositions comprising one of the ?v?8 antagonists, anti-?v?8 antibodies or immunoconjugates, methods for using the compositions, and related subject matter.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: December 19, 2017
    Assignee: The Regents of the University of California
    Inventors: Stephen Nishimura, Jianlong Lou, Jody Lynn Baron, James D. Marks
  • Patent number: 9840559
    Abstract: The present disclosure relates to proteins that bind to CD83 and uses thereof, for example, in therapy, prophylaxis, diagnosis, or prognosis.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: December 12, 2017
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE UNIVERSITY OF QUEENSLAND, DENDROCYTE BIOTECH PTY LTD
    Inventors: Therese Ann Seldon, David John Munster, Derek Nigel John Hart, Martina Louise Jones, Trent Phillip Munro, Stephen Michael Mahler, Eunice Yu Zhou, James D. Marks
  • Publication number: 20170267768
    Abstract: Provided by the present disclosure are antibodies (e.g., scFvs) that include CDRs and human framework regions that confer useful properties upon the antibodies. In certain embodiments, such properties include thermostability (e.g., increased melting temperature), efficient binding to Staphylococcus aureus Protein A, or both. In certain aspects, the antibodies are internalizing antibodies that specifically bind to the tumor associated antigen EphA2.
    Type: Application
    Filed: March 13, 2017
    Publication date: September 21, 2017
    Inventors: James D. Marks, Daryl Drummond, Melissa Geddie, Dmitri Kirpotin, Neeraj Kohli, Alexey Lugovskoy
  • Publication number: 20170233488
    Abstract: This invention provides a method that allows selection of antibodies against cells (e.g., tumor cells) in situ using laser capture microdissection. By restricting antibody selection to binders of internalizing epitopes, a panel of phage antibodies was generated that targets clinically represented prostate cancer antigens.
    Type: Application
    Filed: January 27, 2017
    Publication date: August 17, 2017
    Inventors: BIN LIU, JAMES D. MARKS
  • Publication number: 20170129955
    Abstract: Provided herein are antibodies specific for integrin ?v?8 that change the conformation of ?8 so that, upon binding the ability of ?v?8 to induce release of active, mature TGF? peptide is inhibited.
    Type: Application
    Filed: June 17, 2015
    Publication date: May 11, 2017
    Inventors: Stephen NISHIMURA, Anthony CORMIER, Jody Lynn BARON, James D. MARKS, Lynne MURRAY, Ping TSUI, Yanli WU
  • Publication number: 20170096474
    Abstract: This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: August 16, 2016
    Publication date: April 6, 2017
    Inventors: James D. Marks, Jianlong Lou, Maria Consuelo Garcia Rodriguez, Isin N. Geren
  • Patent number: 9593162
    Abstract: This invention provides a method that allows selection of antibodies against cells (e.g., tumor cells) in situ using laser capture microdissection. By restricting antibody selection to binders of internalizing epitopes, a panel of phage antibodies was generated that targets clinically represented prostate cancer antigens.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: March 14, 2017
    Assignee: The Regents of the University of California
    Inventors: Bin Liu, James D. Marks
  • Publication number: 20160376369
    Abstract: Antibodies that bind to tumor associated antigen CD44 or to tumor associated antigen EphA2, are disclosed herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies, diagnostics, and screening methods.
    Type: Application
    Filed: August 9, 2016
    Publication date: December 29, 2016
    Inventors: Yu Zhou, James D. Marks
  • Patent number: 9527919
    Abstract: The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The Present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: December 27, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Anna M. Wu, Robert E. Reiter, Eric J. Lepin, James D. Marks, Yu Zhou